menu
    • menu
    [{"orgOrder":0,"company":"NEC OncoImmunity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"NEC OncoImmunity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC OncoImmunity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NEC OncoImmunity \/ Undisclosed"},{"orgOrder":0,"company":"NEC OncoImmunity","sponsor":"Vaximm AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"NEC OncoImmunity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC OncoImmunity \/ NEC OncoImmunity","highestDevelopmentStatusID":"4","companyTruncated":"NEC OncoImmunity \/ NEC OncoImmunity"}]

    Find Clinical Drug Pipeline Developments & Deals by NEC OncoImmunity

    Menu

    NEC OncoImmunity

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NEC OncoImmunity

                            Norway arrow
                            Neuroscience
                            Not Confirmed

                            NEC OncoImmunity

                            Norway arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

                            Details : NECVAX-NEO1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 29, 2022

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NEC OncoImmunity

                            Norway arrow
                            Neuroscience
                            Not Confirmed

                            NEC OncoImmunity

                            Norway arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Vaximm AG

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

                            Details : Under the agreement, NOI will acquire VAXIMM’s neoantigen vaccine-related patents including VXM01, which is being developed for the treatment of glioblastoma, license the requisite manufacturing patents, and will take over existing contracts with colla...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 08, 2022

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Vaximm AG

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth